UthPeak™ NMNH, marketed as "The Next-Gen Super NAD+ Enhancer," is a patent-pending crystalline NMNH that has demonstrated a remarkable 10X surge in NAD+ levels.
UthPeak™ NMNH (reduced NMN) has achieved self-affirmed GRAS status following a recent review by an independent panel of qualified scientific and toxicology experts. In accordance with the FDA requirements, UthPeak™ NMNH can be sold, used, and consumed in the U.S. food supply. UthPeak™’s ongoing human clinical trials aim to further validate the safety of NMNH in humans. These trials are anticipated to conclude by the end of 2024.
